Lutris Pharma

About:

Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness.

Website: http://www.lutris-pharma.com

Top Investors: California Institute for Regenerative Medicine

Description:

Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness. The company develops the topical B-Raf inhibitor LUT014, a proprietary small molecule that allows administration of epidermal growth factor receptor (EGFR) inhibitors to patients without the interruptions caused by typical cutaneous side effects. Lutris Pharma was established in 2015 and is based in Tel Aviv-yafo, Israel.